Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

Clinical trial NCT05338450 · TERMINATED

Trial details

NCT number: NCT05338450
Sponsor: Amsterdam UMC, location VUmc
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis Internuclear Ophthalmoplegia

Start date: 2022-08-30
Primary completion: 2025-08-15
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.